
Black Diamond Therapeutics (BDTX) Stock
Clinical stage biotech developing targeted cancer drugs. Here's the price, business snapshot, and what's worth knowing about Black Diamond Therapeutics in November 2026.
Black Diamond Therapeutics (BDTX) is a clinical-stage precision oncology company focused on discovering and developing small-molecule therapies that target oncogenic drivers. The company uses a targeted discovery approach to identify patients whose tumours are driven by specific genetic alterations, aiming for therapies that can offer more selective activity and potentially improved tolerability versus non-targeted treatments. As a smaller-cap biotechnology firm (market cap approximately $225M), progress depends heavily on clinical trial results, regulatory feedback and partnership opportunities. Financial resources, trial enrolment and competitive developments can materially affect prospects. For investors, Black Diamond represents an opportunity-play in precision oncology with asymmetric outcomes: successful trials could materially re-rate the stock, while setbacks could produce significant share volatility. This summary is for educational purposes only and not investment advice; returns are not guaranteed and investors should consider their risk tolerance and seek independent advice.
Black Diamond Therapeutics (BDTX) Stock Forecast
Analyst price target, next 12 months
$11.67
+721.6% vs today's $1.42
Price range over the last 12 months
Close to its 12-month low
Analysts covering Black Diamond Therapeutics have a consensus 12-month target of $11.67, above the current price of $1.42.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Black Diamond Therapeutics’ stock with a target price of $11.67, indicating significant potential for growth.
Financial Health
Black Diamond Therapeutics is showing good cash flow and value per share, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision oncology focus
BDTX targets treatments to tumours with specific genetic drivers, which can improve selectivity — though clinical proof is required and outcomes vary.
Clinical catalysts ahead
Trial readouts and regulatory steps can drive sharp share moves, creating opportunity but also heightening volatility and uncertainty.
Funding and competition
Smaller biotechs depend on capital, partnerships and competitive landscape; these factors can materially affect prospects and share performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.